XBRANE — Xbrane Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK235.93m
- SEK262.45m
- SEK152.35m
Brief: Xbrane Biopharma - Guaranteed New Share Issue Of Maximum Of 2 Million Shares With Preferential Rights For Co's Existing Shareholders At Subscription Price Of Sek 30 Per Share
Brief: Xbrane Biopharma Q4 EBITDA Loss Widens To SEK 30.3 Mln
Brief: Xbrane Biopharma Gets Acceptance To Initiate Xlucane Clinical Trial In US
Brief: Xbrane Biopharma Q3 EBITDA Swings To Profit SEK 62.1 Million
Brief: Xbrane Biopharma Announces Results Of In-Vivo Study Showing Equivalent Tolerability And Pharmacokinetic Profile Of Xlucane Compared To Lucentis
Brief: Xbrane Biopharma: Product Portfolio Update With New Full Strategic Focus On Biosimilars
Brief: Xbrane Biopharma Q2 Revenues Amounted To SEK 4.5 mln
Development Agreement For Xlucane
Development Agreement With Xbrane Biopharma For Xlucane
Brief: Xbrane Biopharma Q1 EBITDA Loss Narrows To SEK 7.3 Million
Brief: Xbrane Biopharma Q4 EBITDA Loss Widens To SEK 18.0 Mln
Brief: Xbrane Biopharma Signs License Agreement In China
Brief: Xbrane Biopharma: Serendipity Ixora Intends To Distribute All Its Shares In Company
Brief: Xbrane says expect to enter into agreement for out-licensing of Spherotide to China in Q1 2018
Brief: Xbrane Biopharma Signs Distribution Agreement In South Korea
Brief: Xbrane Biopharma Q3 EBITDA loss at SEK 8.2 mln
Brief: Xbrane confirms order of Spherotide to value of SEK 8.5 million
Brief: Xbrane Biopharma Q2 pre-tax loss widens to SEK 9.4 million
Brief: Xbrane Biopharma: Spherotide granted market authorization in Iran